On March 13, 2025, Rallybio Corp amended its Sales Agreement with TD Cowen, reducing the amount of common stock it can sell from $100 million to $9.55 million, with TD Cowen earning a commission of up to 3% on sales. As of the filing date, no shares have been sold under this agreement.